Skymab chaired the Advancing Large Molecule Drug Discovery scientific track and presented its strategy for overcoming resistance mechanisms in antibody-drug conjugate therapies through innovative target biology and the proprietary SKYLINK™ platform.
Skymab chaired the Advancing Large Molecule Drug Discovery scientific track and presented its strategy for overcoming resistance mechanisms in antibody-drug conjugate therapies through innovative target biology and the proprietary SKYLINK™ platform.